Mechanism study of PD-1/PD-L1 in tumor and its value of diagnosis and treatment of thyroid cancer

doi:10.3760/cma.j.issn.1673-422X.2020.01.007

Abstract

Abstract:

Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are involved in the regulation of immune checkpoints and are closely related to the occurrence and development of tumors. In thyroid cancer, an increase in PD-L1 expression and an increase in PD-1 positive T cells may be predictive of higher invasiveness and a greater risk of recurrence. Anti-PD-1/PD-L1 therapy has had significant effects in many tumors, but the efficacy in thyroid cancer is still relatively limited, which also requires finding biomarkers those can better predict the efficacy. Further understanding of the mechanism of PD-1/PD-L1, the current research status in thyroid cancer, and biomarkers related to its efficacy may provide new treatment methods and ideas for patients with thyroid cancer.

Key words: Thyroid neoplasms, Immunotherapy, PD-1/PD-L1

Zhang Lizhuo, Qian Yangyang, Zheng Guowan, Ge Minghua. Mechanism study of PD-1/PD-L1 in tumor and its value of diagnosis and treatment of thyroid cancer[J]. Journal of International Oncology, 2020, 47(1): 39-42.

References 34

[1]	Siegel RL, Fedewa SA, Miller KD , et al. Cancer statistics for Hispanics/Latinos, 2015[J]. CA Cancer J Clin, 2015,65(6):457-480. DOI: 10.3322/caac.21314.
[2]	Schlumberger M, Tahara M, Wirth LJ , et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015,372(7):621-630. DOI: 10.1056/NEJMoa1406470.
[3]	Wu X, Gu Z, Chen Y , et al. Application of PD-1 blockade in cancer immunotherapy[J]. Comput Struct Biotechnol J, 2019,17:661-674. DOI: 10.1016/j.csbj.2019.03.006.
[4]	Chowdhury S, Veyhl J, Jessa F , et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants[J]. Oncotarget, 2016,7(22):32318-32328. DOI: 10.18632/oncotarget.8698.
[5]	He J, Hu Y, Hu M , et al. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer[J]. Sci Rep, 2015,5:13110. DOI: 10.1038/srep13110.
[6]	Ahn S, Kim TH, Kim SW , et al. Comprehensive screening for PD-L1 expression in thyroid cancer[J]. Endocr Relat Cancer, 2017,24(2):97-106. DOI: 10.1530/ERC-16-0421.
[7]	Spranger S, Gajewski TF . Impact of oncogenic pathways on evasion of antitumour immune responses[J]. Nat Rev Cancer, 2018,18(3):139-147. DOI: 10.1038/nrc.2017.117.
[8]	Huang Y, Ma C, Zhang Q , et al. CD4⁺ and CD8⁺ T cells have opposing roles in breast cancer progression and outcome [J]. Oncotarget, 2015,6(19):17462-17478. DOI: 10.18632/oncotarget.3958.
[9]	Ohaegbulam KC, Assal A, Lazar-Molnar E , et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J]. Trends Mol Med, 2015,21(1):24-33. DOI: 10.1016/j.molmed.2014.10.009.
[10]	Wei SC, Levine JH, Cogdill AP , et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade[J]. Cell, 2017, 170(6): 1120-1133.e17. DOI: 10.1016/j.cell.2017.07.024.
[11]	Sanborn RE, Pishvain MJ, Callahan MK , et al. Phase Ⅰ results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events[J]. Cancer Res, 2016,76(14):7614. DOI: 10.1158/1538-7445.AM2016-CT023.
[12]	Hsieh AM, Polyakova O, Fu G , et al. Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions[J]. Oncotarget, 2018,9(28):19767-19782. DOI: 10.18632/oncotarget.24833.
[13]	Fu G, Polyakova O, Macmillan C , et al. Programmed death-ligand 1 expression distinguishes invasive encapsulated follicular variant of papillary thyroid carcinoma from noninvasive follicular thyroid neoplasm with papillary-like nuclear features[J]. EBioMedicine, 2017,18:50-55. DOI: 10.1016/j.ebiom.2017.03.031.
[14]	Bastman JJ, Serracino HS, Zhu Y , et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer[J]. J Clin Endocrinol Metab, 2016,101(7):2863-2873. DOI: 10.1210/jc.2015-4227.
[15]	Antonelli A, Ferrari SM, Fallahi P . Current and future immunotherapies for thyroid cancer[J]. Expert Rev Anticancer Ther, 2018,18(2):149-159. DOI: 10.1080/14737140.2018.1417845.
[16]	Mehnert JM, Varga A, Brose MS , et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer[J]. BMC Cancer, 2019,19(1):196. DOI: 10.1186/s12885-019-5380-3.
[17]	Prasongsook N, Kumar A, Chintakuntlawar AV , et al. Survival in response to multimodal therapy in anaplastic thyroid cancer[J]. J Clin Endocrinol Metab, 2017,102(12):4506-4514. DOI: 10.1210/jc.2017-01180.
[18]	Cantara S, Bertelli E, Occhini R , et al. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer[J]. Endocrine, 2019,64(1):122-129. DOI: 10.1007/s12020-019-01865-5.
[19]	Gunda V, Gigliotti B, Ndishabandi D , et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer[J]. Br J Cancer, 2018,119(10):1223-1232. DOI: 10.1038/s41416-018-0296-2.
[20]	Gunda V, Gigliotti B, Ashry T , et al. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer[J]. Int J Cancer, 2019,144(9):2266-2278. DOI: 10.1002/ijc.32041.
[21]	Kollipara R, Schneider B, Radovich M , et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer[J]. Oncologist, 2017,22(10):1149-1151. DOI: 10.1634/theoncologist.2017-0096.
[22]	Iyer PC, Dadu R, Gule-Monroe M , et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma[J]. J Immunother Cancer, 2018,6(1):68. DOI: 10.1186/s40425-018-0378-y.
[23]	Chintakuntlawar AV, Yin J, Foote RL , et al. A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer[J]. Thyroid, 2019,29(1):1615-1622. DOI: 10.1089/thy.2019.0086.
[24]	Elisei R, Pinchera A . Advances in the follow-up of differentiated or medullary thyroid cancer[J]. Nat Rev Endocrinol, 2012,8(8):466-475. DOI: 10.1038/nrendo.2012.38.
[25]	Yamaga LYI, Cunha ML, Campos Neto GC , et al. ⁶⁸Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with ¹¹¹In-octreotide SPECT/CT and conventional imaging [J]. Eur J Nucl Med Mol Imaging, 2017,44(10):1695-1701. DOI: 10.1007/s00259-017-3701-9.
[26]	Schlumberger M, Elisei R, Müller S , et al. Overall survival analysis of EXAM, a phase Ⅲ trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma[J]. Ann Oncol, 2017,28(11):2813-2819. DOI: 10.1093/annonc/mdx479.
[27]	Shi X, Yu PC, Lei BW , et al. Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical recurrence/persistent disease in medullary thyroid carcinoma[J]. Thyroid, 2019,29(9):1269-1278. DOI: 10.1089/thy.2019.0079.
[28]	Kang J, Demaria S, Formenti S . Current clinical trials testing the combination of immunotherapy with radiotherapy[J]. J Immunother Cancer, 2016,4:51. DOI: 10.1186/s40425-016-0156-7.
[29]	Hellmann MD, Nathanson T, Rizvi H , et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer[J]. Cancer Cell, 2018, 33(5): 843-852.e4. DOI: 10.1016/j.ccell.2018.03.018.
[30]	Sunshine J, Taube JM . PD-1/PD-L1 inhibitors[J]. Curr Opin Pharmacol, 2015,23:32-38. DOI: 10.1016/j.coph.2015.05.011.
[31]	Hellmann MD, Ciuleanu TE, Pluzanski A , et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018,378(22):2093-2104. DOI: 10.1056/NEJMoa1801946.
[32]	Vanderwalde A, Spetzler D, Xiao N , et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients[J]. Cancer Med, 2018,7(3):746-756. DOI: 10.1002/cam4.1372.
[33]	Bagley SJ, Kothari S, Aggarwal C , et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer[J]. Lung Cancer, 2017,106:1-7. DOI: 10.1016/j.lungcan.2017.01.013.
[34]	Kamphorst AO, Pillai RN, Yang S , et al. Proliferation of PD-1⁺ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients [J]. Proc Natl Acad Sci U S A, 2017,114(19):4993-4998. DOI: 10.1073/pnas.1705327114.